Astrazeneca PLC Sponsored ADR (AZN)

Just as fears of Fed tightening and a trade war created buying opportunities in tech and elsewhere in late 2018, arguably overblown fears about the Delta variant's economic impact are creating opportunities now.

Those rattles you hear on the COVID, Fed and political fronts are reasons to tread carefully in the markets.

The public seems to have resigned itself to dealing with a greater degree of inflation for longer than anything I would have considered to be 'transitory.' The again, the public is often as wrong as the Fed.

I prefer the bear put spread over the covered equity play due to the decreased risk to principal, despite the capped potential for profit.

This drugmaker is making a historic upside breakout. Let's check the charts.

Debt-free and poised to gain from its COVID-19 vaccine demand, MRNA could inject some life into your investment plan.

UPS and FDX are both in serious rally mode, yet in very different places in terms of technical development.

Plus, ServiceNow is a stock worth stalking and Amazon is a stock worth celebrating.

So far, for the season, the blended rate of earnings growth for the first quarter now stands at an incredible 33.8%.

Don't forget, this is a very large company with a lot more than the vaccine going on.

The AZN affair exposes the seedy underbelly of drug manufacturing, and the COVID-19 vaccine is certainly a drug.

Lies, damn lies, and statistics in the vaccine age, as Hong Kong and Macau stop administering the Pfizer/BioNTech drug.

Ever think you would see the day when all cash was digital so the federal government could place a negative interest rate (tax) on savings? I can see this coming from a mile away.

Here's my view on this space and where the money is to be made.

COVID numbers stopped improving a while ago, even with ever-improving rates of vaccination. Just what is going on here?

A break in a key support level could precipitate further declines in the life sciences company's shares.

Dips in the shares of Redhill Biopharma and FibroGen Inc. provided the chance for the author to employ his covered call strategy.

Dynavax Technologies has inked a supply deal related to a Covid-19 vaccine that could greatly increase its revenue stream.

Who knew high finance was so easy? And why the heck was I working so hard? Fundamental analysis is so 1980s.

Aggressive traders might want to look past any near-term price weakness and consider a small long position.

We have to take both the private sector and the states out of the equation, and adopt the process that wiped out Polio.

While there are certainly some things to like about AZN, I don't think this vaccine, nor the UK emergency authorization, make it investable.

I did something on Tuesday that I never thought that I would do again. I bought some Intel.

I think BA returns to normal as we do, as the airlines do... but with the defense contracting business as a foundation to rely upon.

The Russell 2000 is now up 7% for December, twice the increase for the Nasdaq Composite.

Ending the pandemic swiftly appears unlikely, so here's how to look at key stocks and sectors right now -- especially as concerns of new lockdowns grow.

I am staying away from this name for now, despite the Alexion acquisition and vaccine promise.